TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05113316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messy Memories App
Description: The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition.
Study: NCT06203483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: A linear ultrasound probe will be placed medial to the patella, the probe will be advanced to cephalad, and the superficial femoral artery will be visualized. The block site will be confirmed by injecting 5 ml of saline around the saphenous nerve in the subsartorial region under ultrasound guidance. Then, 30 ml of local anesthetic solution containing 0.25% bupivacaine (Marcain 0.5% AstraZeneca, England) will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG block
Description: The probe will be placed at the anterior superior level of spina iliaca, parallel to the inguinal ligament. The probe will be scanned gradually towards the caudal. After the anterior inferior of the spina iliaca is visible, the probe will be slightly turned medially until the hyperechoic shadow of the superior pubic ramus is visible. The psoas muscle tendon will be visualized above the superior pubic ramus, then 5 ml of saline will be injected under the psoas tendon and the block location will be confirmed. After that 30 ml of 0.25% bupivacaine will be administered.
Study: NCT05494268

Intervention type: DRUG
Intervention: Carbohydrate
Description: Preoperative Carbohydrate Loading Drink
Study: NCT05386147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)
Description: see arm description
Study: NCT05280665

Intervention type: OTHER
Intervention: Specialization
Description: * Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~* Who identified themselves as primarily gastric surgeons during the study period~* Whose annual gastric cancer surgery volume is more than 21
Study: NCT05989139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NPPV/HFNC
Description: Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each. NPPV will be delivered through a full-face mask with a FiO2 starting at 100% and then titrated to achieve an SpO2 of 92-98%. Expiratory positive airway pressure (PEEP) will be firstly set to 5 cmH2O and then increased to a maximum of 15 cmH2O based on SpO2. Pressure support (PS) will be set to an initial value of 10 cmH2O and then increased if signs of respiratory distress persisted or worsened to a maximum value of 20 cmH2O. After 40 minutes, patient is shifted to HFNC ventilation support for 40 minutes.~At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNC/NPPV
Description: Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each.~HFNC oxygen therapy will start at a flow rate of 60 L/min and will be gradually decreased by 5 cmH2O at time if the patient experienced discomfort. FiO2 will be started at 100% and then titrated to maintain a peripheral oxygen saturation of 92%-98%. Active heating and humidification were provided using MR850, Fisher and Paykel, with a temperature chamber of 37°C. After 40 minutes, patient is shifted to NPPV ventilation support for 40 minutes At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient.
Study: NCT06425653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization
Study: NCT04878107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDRT
Description: low dose radation therapy
Study: NCT05814718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified BEAM
Description: Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEAM
Description: BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
Study: NCT06072625

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extra virgin organic olive oil (ULTRA PREMIUM)
Description: Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
Study: NCT05623748

Intervention type: PROCEDURE
Intervention: CTCs isolation/purification and cell number expansion
Description: In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.

Intervention type: PROCEDURE
Intervention: CTCs isolation/purification and cell number expansion
Description: In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
Study: NCT06045065

Intervention type: OTHER
Intervention: Fresh tumor sampling
Description: Patient samples will be collected during neurosurgical resection. .

Intervention type: OTHER
Intervention: Fresh tumor sampling
Description: Patient samples will be collected during neurosurgical resection. .
Study: NCT05158530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Exercises
Description: 4 weeks protocol~1. Deep breathing Exercises\* 10 Reps 3 sets~2. Postural drainage (10 minutes \* 2 sets /day)~3. Incentive spirometry\* 10 Reps 3 sets~4. Bed activities (Active ankle and hand pumping exercise \* 10 Reps 3 sets)
Study: NCT06339606

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Biospecimens, including maternal blood and cervical mucus will be collected serially during pregnancy. After delivery tissue samples from the placenta and umbilical cord blood will be collected.

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Biospecimens, including maternal blood and cervical mucus will be collected serially during pregnancy. After delivery tissue samples from the placenta and umbilical cord blood will be collected.
Study: NCT05056558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
Study: NCT05711875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) glasses
Description: During the Non Stress Test (NST), the pregnant women in the experimental group watched a video of nature scenery with Virtual Reality (VR) glasses for 10 minutes
Study: NCT04772300

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter
Description: PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)
Description: PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery
Study: NCT06435819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent (ECA)
Description: A computer-animated character that can explain a medical illustration to laypersons.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent (ECA)
Description: A computer-animated character that can explain a medical illustration to laypersons.
Study: NCT05316493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Description: dietary guidance, exercise guidance, lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Description: dietary guidance, exercise guidance, lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Description: dietary guidance, exercise guidance, lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Description: dietary guidance, exercise guidance, lifestyle intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 160 MG Oral Tablet
Description: enrolled participants will take Megestrol Acetate 160mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 160 MG Oral Tablet
Description: enrolled participants will take Megestrol Acetate 160mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
Description: enrolled patients will be treated with LNG-IUS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
Description: enrolled patients will be treated with LNG-IUS.
Study: NCT05881512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Upper Airway Stimulation Device
Description: Multiple frequency stimulation of the hypoglossal nerve
Study: NCT05118711

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory fitness
Description: Cardiopulmonary exercise testing
Study: NCT04674748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB086550
Description: Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
Study: NCT06192836

Intervention type: PROCEDURE
Intervention: Manual Removal 1
Description: 1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed

Intervention type: PROCEDURE
Intervention: Manual Removal 2
Description: 1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed

Intervention type: PROCEDURE
Intervention: Controlled Cord Traction 1
Description: 1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed

Intervention type: PROCEDURE
Intervention: Controlled Cord Traction 2
Description: 1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed

Intervention type: PROCEDURE
Intervention: Controlled Cord Traction+Uterine Massage 1
Description: 1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed after placental delivery

Intervention type: PROCEDURE
Intervention: Controlled Cord Traction+Uterine Massage 2
Description: 1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. Additional uterine massage for one minute duration will be performed after uterine incision is closed
Study: NCT06444945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating pad
Description: Heating pad will be used for heating purpose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating pad
Description: Heating pad will be used for heating purpose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation(TENS)
Description: TENS is used for symptomatic pain relief

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation(TENS)
Description: TENS is used for symptomatic pain relief

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with movement (MWM)
Description: It provides short term pain relief and to restore pain-free, functional movements by achieving full range at the joint

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kaltenborn joint mobilization
Description: The purpose of joint mobilization is to restore normal, painless joint function. In restricted joints, this involves the restoration of joint play to normalize the roll-gliding that is essential to active movement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Training exercise
Description: Resistance training increases muscle strength by making your muscles work against a weight or force.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Training exercise
Description: Resistance training increases muscle strength by making your muscles work against a weight or force.
Study: NCT04340349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine 8 MG
Description: TMPRSS2 blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bromhexine 8 MG
Description: TMPRSS2 blocker
Study: NCT05975736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search only for masses
Description: Participants search the simulated mammogram for simulated masses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search only for masses
Description: Participants search the simulated mammogram for simulated masses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search only for calcifications
Description: Participants search the simulated mammogram for simulated calcifications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search only for calcifications
Description: Participants search the simulated mammogram for simulated calcifications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search for both together
Description: Search the simulated mammogram for both simulated masses and simulated calcifications at the same time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search for both together
Description: Search the simulated mammogram for both simulated masses and simulated calcifications at the same time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search for one after the other
Description: Search the simulated mammogram for first for simulated masses and then for simulated calcifications sequentially (or vice versa).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search for one after the other
Description: Search the simulated mammogram for first for simulated masses and then for simulated calcifications sequentially (or vice versa).
Study: NCT05808075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NovaProTM Fill Universal Dental Composite
Description: NovaProTM Fill Universal ,Nanova product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NovaProTM Fill Universal Dental Composite
Description: NovaProTM Fill Universal ,Nanova product
Study: NCT01799122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)
Study: NCT05408572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010 (IL12-FHAB)
Description: SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010 (IL12-FHAB)
Description: SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
Study: NCT05118711

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory fitness
Description: Cardiopulmonary exercise testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function
Description: Body plethysmography
Study: NCT06184685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sahasthara Microemulsion
Description: All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Microemulsion
Description: All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
Study: NCT05433701

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: * Verify the setup position and respiration of patients as in the simulation CT image.~* To precisely align the tumor prior to each treatment, cone-beam CT and gated fluoroscopy using the On-board Imager mounted on the linear accelerator are performed.~* The Real-time Position Management system is used to monitor the accuracy of breathing phase during treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: - RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.
Study: NCT05128071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to placebo twice daily
Study: NCT05761288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intraoperative microbreaks and exercises
Description: Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend.
Study: NCT04543877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).